10790 Roselle Street
Tsvi Goldenberg, chairman and CEO
Immusol Inc. uses its Inverse Genomics technology platform to discover and functionally validate therapeutic drug target genes in the areas of cancer, viral disease (HIV and hepatitis C), neurodegenerative disease (Alzheimer’s and Parkinson’s diseases), allergy/inflammation and obesity/diabetes, and to develop ribozyme, antibody and small-molecule drugs.
The company has identified and functionally validated therapeutic drug target genes for cancer and infectious viral diseases. Its drug target portfolio contains about 70 drug targets in various stages of development.
Immusol has applied its ribozyme technology to develop a variety of ribozyme drug candidates, including VitrenASE (for proliferative eye disease), ProliferASE (for psoriasis and other dermal conditions) and RestenASE (for coronary restenosis).
Discovery collaboration of small-molecule drug candidates for the treatment of HIV: NeoGenesis Pharmaceuticals Inc.
Five-year oncology discovery and development collaboration: Novartis Pharma AG.
Functional genomics collaboration for drug discovery of genes relating to cancer metastasis: Chugai Biopharmaceuticals Inc.
Strategic alliance for the development of fully human antibody therapeutic products: Medarex Inc.
Other existing and former collaborations include Pfizer Inc., the University of Colorado at Denver and the University of California, San Diego.